TY - JOUR
T1 - Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
AU - Ellingson, Benjamin M.
AU - Bendszus, Martin
AU - Boxerman, Jerrold
AU - Barboriak, Daniel
AU - Erickson, Bradley J.
AU - Smits, Marion
AU - Nelson, Sarah J.
AU - Gerstner, Elizabeth
AU - Alexander, Brian
AU - Goldmacher, Gregory
AU - Wick, Wolfgang
AU - Vogelbaum, Michael
AU - Weller, Michael
AU - Galanis, Evanthia
AU - Kalpathy-Cramer, Jayashree
AU - Shankar, Lalitha
AU - Jacobs, Paula
AU - Pope, Whitney B.
AU - Yang, Dewen
AU - Chung, Caroline
AU - Knopp, Michael V.
AU - Cha, Soonme
AU - Van Den Bent, Martin J.
AU - Chang, Susan
AU - Al Yung, W. K.
AU - Cloughesy, Timothy F.
AU - Wen, Patrick Y.
AU - Gilbert, Mark R.
AU - Whitney, Andrew
AU - Sandak, David
AU - Musella, Al
AU - Haynes, Chas
AU - Wallace, Max
AU - Arons, David F.
AU - Kingston, Ann
N1 - Publisher Copyright:
© 2015 The Author(s).
PY - 2015/9/1
Y1 - 2015/9/1
N2 - A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.
AB - A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.
KW - Brain Tumor Imaging Protocol
KW - MRI
KW - clinical trials
KW - glioblastoma
UR - http://www.scopus.com/inward/record.url?scp=84940726872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940726872&partnerID=8YFLogxK
U2 - 10.1093/neuonc/nov095
DO - 10.1093/neuonc/nov095
M3 - Review article
C2 - 26250565
AN - SCOPUS:84940726872
SN - 1522-8517
VL - 17
SP - 1188
EP - 1198
JO - Neuro-oncology
JF - Neuro-oncology
IS - 9
ER -